The efficacy of Saccharomyces boulardii sachets in adjuvant therapy of liver cirrhosis patients with spontaneous bacterial peritonitis

Abstract

Objective To observe the adjuvant therapy efficacy of Saccharomyces boulardii sachets in liver cirrhosis patients with spontaneous bacterial peritonitis(SBP). Methods 72 liver cirrhosis patients with SBP were randomly divided into the observation group and control group.The patients in the control group(30 cases) were given routine medical treatment such as anti-infection,correction of hypoproteinemia,liver protection,and diuresis,etc.At the base of the control group,the patients in the observation group(32 cases) were orally given Saccharomyces boulardii(Baili Pharmaceutical Factory,French)0.5g for one time,two times daily for 10 days.The changes of serum interleukin-6(IL-6),pmcalcitonin(PCT) and hypersensitive c-reactive protein(hs-CRP)levels in the two groups were observed and compared before and after treatment,and curative effect and safety were also observed. Results Before treatment,the serum IL-6,PCT and hs-CRP levels in the two groups had no obviously statistical difference(all P> 0.05),but after treatment,the serum IL-6, PCT and hs-CRP levels of the observation group were much lower than those of the control group[(60.50± 19.10)pg/m L vs(98.32±17.20)pg/m L,(1.80±0.34)μg/L vs(6.38±3.56)μg/L,(6.20±4.15)mg/L vs(20.28±8.30)mg/L,t= 8.147,7.246,8.529,all P 0.05). Conclusion Saccharomyces boulardii can significantly reduce serum IL-6,PCT and hs-CRP levels of liver cirrhosis patients with SBP,and reduce inflammation reaction to control development of SBP. Key words: Peritonitis; Yeasts; Interleukin-6; C-Reactive Protein